BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 20925013)

  • 21. Ranolazine: an antianginal drug with antiarrhythmic properties.
    Tamargo J; Caballero R; Delpón E
    Expert Rev Cardiovasc Ther; 2011 Jul; 9(7):815-27. PubMed ID: 21809962
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [New agents for the therapy of angina pectoris].
    Meinertz T; Köster R
    Internist (Berl); 2011 Jul; 52(7):894-6, 898-900. PubMed ID: 21713611
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem.
    Cocco G; Rousseau MF; Bouvy T; Cheron P; Williams G; Detry JM; Pouleur H
    J Cardiovasc Pharmacol; 1992 Jul; 20(1):131-8. PubMed ID: 1383622
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gender comparison of efficacy and safety of ranolazine for chronic angina pectoris in four randomized clinical trials.
    Wenger NK; Chaitman B; Vetrovec GW
    Am J Cardiol; 2007 Jan; 99(1):11-8. PubMed ID: 17196454
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial.
    Wilson SR; Scirica BM; Braunwald E; Murphy SA; Karwatowska-Prokopczuk E; Buros JL; Chaitman BR; Morrow DA
    J Am Coll Cardiol; 2009 Apr; 53(17):1510-6. PubMed ID: 19389561
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of ranolazine in angina, heart failure, arrhythmias, and diabetes.
    Sossalla S; Maier LS
    Pharmacol Ther; 2012 Mar; 133(3):311-23. PubMed ID: 22133843
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ranolazine: a new approach to treating an old problem.
    Reddy BM; Weintraub HS; Schwartzbard AZ
    Tex Heart Inst J; 2010; 37(6):641-7. PubMed ID: 21224931
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE).
    Koren MJ; Crager MR; Sweeney M
    J Am Coll Cardiol; 2007 Mar; 49(10):1027-34. PubMed ID: 17349881
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ranolazine. A metabolic modulator for the treatment of chronic stable angina.
    Anderson JR; Nawarskas JJ
    Cardiol Rev; 2005; 13(4):202-10. PubMed ID: 15949056
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New treatment options for late Na current, arrhythmias, and diastolic dysfunction.
    Maier LS
    Curr Heart Fail Rep; 2012 Sep; 9(3):183-91. PubMed ID: 22767404
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Late sodium current inhibition as a new cardioprotective approach.
    Hale SL; Shryock JC; Belardinelli L; Sweeney M; Kloner RA
    J Mol Cell Cardiol; 2008 Jun; 44(6):954-967. PubMed ID: 18462746
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ranolazine: new approach for the treatment of stable angina pectoris.
    Stanley WC
    Expert Rev Cardiovasc Ther; 2005 Sep; 3(5):821-9. PubMed ID: 16181027
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of ranolazine on cardiovascular system.
    Bonadei I; Vizzardi E; Quinzani F; Piovanelli B; Rovetta R; D'Aloia A; Cas LD
    Recent Pat Cardiovasc Drug Discov; 2011 Sep; 6(3):215-21. PubMed ID: 21867482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ranolazine: a new approach to management of patients with angina.
    Tafreshi MJ; Fisher E
    Ann Pharmacother; 2006 Apr; 40(4):689-93. PubMed ID: 16595572
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ranolazine, a novel anti-anginal agent, does not alter isosorbide dinitrate- or sildenafil-induced changes in blood pressure in conscious dogs.
    Zhao G; Messina E; Xu X; Ochoa M; Serpillon S; Shryock J; Belardinelli L; Hintze TH
    Eur J Pharmacol; 2006 Jul; 541(3):171-6. PubMed ID: 16777088
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ranolazine: effects on ischemic heart.
    Rognoni A; Barbieri L; Cavallino C; Bacchini S; Veia A; Degiovanni A; Rametta F; Nardi F; Lazzero M; Lupi A; Bongo AS
    Recent Pat Cardiovasc Drug Discov; 2013 Dec; 8(3):197-203. PubMed ID: 23961914
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ranolazine (ranexa) for chronic angina.
    Med Lett Drugs Ther; 2006 Jun; 48(1236):46-7. PubMed ID: 16770296
    [No Abstract]   [Full Text] [Related]  

  • 38. Ranolazine in patients with angina and coronary artery disease.
    Scirica BM; Morrow DA
    Curr Cardiol Rep; 2007 Jul; 9(4):272-8. PubMed ID: 17601393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions.
    Chaitman BR
    Circulation; 2006 May; 113(20):2462-72. PubMed ID: 16717165
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmacology at work for cardio-oncology: ranolazine to treat early cardiotoxicity induced by antitumor drugs.
    Minotti G
    J Pharmacol Exp Ther; 2013 Sep; 346(3):343-9. PubMed ID: 23818683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.